MOP Platform for T Cell Targeting for Autoimmune and Cancer Applications through CAR-T Therapy

T cells are typically known to provide effective natural defense against infection and diseases.

However, in cases where disease develops due to naturally occurring mutations in the body, like autoimmune diseases and cancers, T cells can become ineffective at recognizing abnormal cells. To solve this issue, T-cells can be modified to express chimeric antigen receptors (CAR) to recognize antigens on the surface of specific cells.

Currently in the industry, typical CAR-T therapy involves collecting T-cells from the patient, engineering CAR-T cells ex vivo, and then infusing the CAR-T cells back into the patient’s bloodstream. This can be a time-consuming and difficult process for patients to go through while struggling with these diseases. mRNA allows for the potential engineering of CAR-T cells in the body without having to extract them from the patient first. By directly targeting the T-cells, mRNA can program the T-cell to express the CAR after transfection in the body.

Most mRNA companies are trying to target T-cells by modifying the LNP delivery formulation, but Combined Therapeutic’s complementary approach is to apply their Multi-Organ Protection (MOP) Platform to the mRNA, allowing for a more selective targeting of the T-cells and preventing expression of the CAR in healthy cells.

By utilizing this mRNA-MOP Platform, CAR-T treatments can be dosed directly in one-sitting while also being safer by protecting key organs.